» Spontaneous Reporting Systems for Adverse Drug Reactions

Spontaneous Reporting Systems for Adverse Drug Reactions

1960
Healthcare professional entering data for adverse drug reactions in public health epidemiology.

Spontaneous Reporting Systems (SRS) are a cornerstone of post-marketing drug safety surveillance. Healthcare professionals and patients voluntarily submit reports of suspected adverse drug reactions (ADRs) to a central database. While subject to under-reporting and bias, these systems are crucial for detecting rare, unexpected, or long-latency ADRs that may not be identified during pre-market clinical trials.

Spontaneous Reporting Systems (SRS) form the foundation of passive surveillance in pharmacovigilance. The core principle is the unsolicited reporting of suspected adverse 事件 by individuals, primarily healthcare providers but increasingly patients themselves. The UK’s Yellow Card Scheme, launched in 1964, is one of the earliest and most well-known examples. In the United States, the FDA Adverse Event Reporting System (FAERS) serves a similar function.

The primary strength of SRS is its broad scope. It can collect data on all drugs and all patients for an indefinite period, making it an invaluable tool for identifying safety issues that are too rare to be detected in the relatively small and controlled environment of pre-approval clinical trials. These systems are particularly effective at detecting ‘Type B’ (bizarre) adverse reactions, which are not related to the drug’s known pharmacological action.

However, SRS has significant limitations. The most critical is under-reporting; it is estimated that only a small fraction of all ADRs are ever reported. The data quality can be inconsistent, often lacking detailed clinical information. Furthermore, because there is no systematic data collection, it is impossible to calculate the incidence rate of an ADR, as the total number of patients exposed to the drug (the denominator) is unknown. Reports are also subject to various biases, such as notoriety of a drug leading to increased reporting (stimulated reporting). Despite these weaknesses, SRS remains an indispensable, cost-effective 方法 for generating safety signals that can then be investigated using more rigorous epidemiological studies.

UNESCO Nomenclature: 3211
– Public Health

类型

Abstract System

Disruption

Incremental

使用方法

Widespread Use

Precursors

  • the thalidomide tragedy highlighting the need for post-marketing surveillance
  • the establishment of national health services and regulatory bodies
  • advances in database technology and data management
  • the tradition of medical case reporting in journals

应用

  • signal detection for new adverse drug reactions
  • informing regulatory actions like label changes or drug withdrawal
  • generating hypotheses for further pharmacoepidemiological studies
  • populating global databases like VigiBase
  • monitoring the safety of vaccines (e.g., VAERS in the US)

专利:

Potential Innovations Ideas

级别需要会员

您必须是!!等级!!会员才能访问此内容。

立即加入

已经是会员? 在此登录
Related to: spontaneous reporting system, SRS, adverse drug reaction, ADR, pharmacovigilance, post-marketing surveillance, signal detection, Yellow Card Scheme, FAERS, under-reporting.

发表回复

您的邮箱地址不会被公开。 必填项已用 * 标注

迎接新挑战
Mechanical Engineer, Project, Process Engineering or R&D Manager
有效的产品开发

可在短时间内接受新的挑战。
通过 LinkedIn 联系我
Plastic metal electronics integration, Design-to-cost, GMP, Ergonomics, Medium to high-volume devices & consumables, Lean Manufacturing, Regulated industries, CE & FDA, CAD, Solidworks, Lean Sigma Black Belt, medical ISO 13485

我们正在寻找新的赞助商

 

您的公司或机构从事技术、科学或研究吗?
> 给我们发送消息 <

接收所有新文章
免费,无垃圾邮件,电子邮件不分发也不转售

或者您可以免费获得完整会员资格以访问所有受限制的内容>这里<

Historical Context

(if date is unknown or not relevant, e.g. "fluid mechanics", a rounded estimation of its notable emergence is provided)

Related Invention, Innovation & Technical Principles

滚动至顶部

你可能还喜欢